The National Archives in Washington held a discussion Thursday about the case that set the museum world on edge and raised alarms about the vulnerability of archives, museums and research collections nationwide.
Since there are several other such meds being developed by other drugmakers, including Lilly, the results raised questions not only about regulatory approval, but the ability of Bydureon to establish a needed edge.